Enlibrium Secures $15,000,000 Series A Funding

  • Feed Type
  • Date
    12/4/2015
  • Company Name
    Enlibrium
  • Mailing Address
    Undisclosed San Diego, CA 92130 USA
  • Company Description
    Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The financing is expected to provide sufficient capital to advance Enlibrium’s lead compounds through Phase 1 clinical trials.
  • M&A Terms
  • Venture Investor
    Avalon Ventures
  • Venture Investor
    TPG Biotech
  • Venture Investor
    Correlation Ventures
  • Venture Investor
    Osage Partners